title: Safety and efficacy of combined use of low molecular weight heparin (enoxaparin, lovenox) and glycoprotein IIb/IIIa receptor antagonist (eptifibatide, integrelin) during nonemergent coronary and peripheral vascular intervention.
abstract: Coronary and peripheral intervention requires intraprocedural anticoagulation to prevent intraluminal thrombosis. Traditionally, unfractionated heparin (UFH) is administered during the procedure to achieve activated clotting time (ACT) of 300 to 400 seconds. When the intravenous IIb/IIIa antagonists are also used, the recommended ACT is 250 to 300 seconds because higher anticoagulation (ACT, 300-400 seconds) is accompanied by an unacceptable bleeding complication rate without added benefits. Because low molecular weight heparin has a more predictable anticoagulant effect and a higher anti-factor Xa/anti-factor IIa ratio, allows better bioavailability, is resistant to inhibition by activated platelets, and does not require routine monitoring using ACT, its use for intraprocedural anticoagulation (instead of UFH) has been an area of increasing interest. The safety and efficacy of coadministration of low molecular weight heparin with IIb/IIIa antagonists have not been adequately evaluated. We report a study of prospective evaluation of the safety and efficacy of combined use of intravenous enoxaparin and intravenous eptifibatide during nonemergent coronary and peripheral vascular intervention in 93 consecutive procedures performed on 56 patients. The procedural success rate was 99% (92/93 procedures), the acute clinical success rate was 98% (54/55 patients), the major bleeding complication rate was 2% (1/56 patients), and the vascular complication rate was 0.0%. In conclusion, the use of intravenous enoxaparin in conjunction with intravenous eptifibatide during nonemergent coronary and peripheral vascular intervention is safe and effective and eliminates the need for routine measurement of ACT during the procedure.
authors.affiliation: Section of Cardiology and Endovascular Therapeutics, Mount Sinai Hospital Chicago, IL 60608, USA. khos@sinai.org
authors.forename: Sandeep
authors.initials: S
authors.lastname: Khosla
authors.forename: Binu
authors.initials: B
authors.lastname: Kunjummen
authors.forename: Mayra
authors.initials: M
authors.lastname: Guerrero
authors.forename: Ravi
authors.initials: R
authors.lastname: Manda
authors.forename: Mansoor
authors.initials: M
authors.lastname: Razminia
authors.forename: Atul
authors.initials: A
authors.lastname: Trivedi
authors.forename: Vasundhara
authors.initials: V
authors.lastname: Vidyarthi
authors.forename: Monther
authors.initials: M
authors.lastname: Elbazour
authors.forename: Aziz
authors.initials: A
authors.lastname: Ahmed
authors.forename: David
authors.initials: D
authors.lastname: Lubell
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use*; D015897:Comorbidity; D003327:Coronary Disease / Q000628:therapy*; D004359:Drug Therapy, Combination; D017984:Enoxaparin / Q000008:administration & dosage / Q000627:therapeutic use*; D000077542:Eptifibatide; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D011446:Prospective Studies
chemical_list: D000925:Anticoagulants; D017984:Enoxaparin; D010455:Peptides; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077542:Eptifibatide